Immunoassays for drug screening are called 'qualitative' or 'semiquantitative' by the manufacturers of these tests and they urgently recommend the user to verify each result exceeding the recommended cut-off value by a confirmation test. For therapeutic drug monitoring assays or for the determination of tumour markers or hormones, similar recommendations are not given, although the same analytical technologies are used for these assays.
Introduction
screening and testing people with unexplained, abnorn . ,, , f mal behaviour. There are several reasons for screening people for drug abuse. The primary uses are however, surveillance of During the past few years, the number of samples subformer drug addicts taking part in drug abuse rehabilita-mitted for drug screening has increased dramaticully in tion programs, routine c on the Job' or pre-employment our Institution and can constitute up to 350 urine sam-ples a day. New methodological approaches had to be cvaluated in order to guarantee a rapid turnover äs well äs a reliable perfomiance of the methods used in drug testing. The Obligation to confirm the increasing number of positive results by an alternative (reference) method (e.g. GC-MS) requires additional personnel and increases costs accordingly.
Modern immunological tests designed for drug screening using highly automated Systems (e.g. EMIT II, Syva; TDx, Abbott) are described äs being 'semiquantitative' in the method descriptions supplied by the manufacturers, without giving detailed Information on the assay performance and how the data given (e. g. limit of detection) were obtained.
Drug testing is a 'forensic toxicological' analysis, and äs Peat stated: "... this requires a strict chain of custody, security of the laboratory, appropriate and adequate quality control procedures, and the use of legally defensible analytical procedures (1)". However, it is astonishing that for tests whose results have such far-reaching consequences (false negative äs well äs false positive results), the performance of the assays, especially the limit of detection, the limit of quantification and the threshold concentration have not been evaluated in studies by using standardized and acceptable mathematical procedures.
It has been known for many years that the imprecision of an assay depends upon the concentration of the analyte, but it was not until the introdüction of radioimmunoassays that thorough studies have been published on the issue (2) . Further publications have shown that this observation is also valid for other procedures (3) . At each analyte concentration a specific imprecision must therefore be expected and general data cannot be given.
Despite the fact that several authors (2-4) have proposed the derivation of the analytical limit from a precision profile, most method descriptions or evahiations use procedures which are statistically not clearly defmed. To our knowledge, no standardized mathematical approaches have been used until now to assess the performance of immunoassays for drugs of abuse.
A standardized mathematical procedure has been described in the literature for the evaluation of cyclosporin (3) and prostate specific antigen (5). Data derived from human sample material was used to determine the variance ftmction, which was subsequently applied to determine the analytical limits. No artificial Standard material with a matrix different from human samples had to be used. The characteristics which could be derived from. the variance function were: (I) the precision profile, (II) the limit of detection (LD) and (III) the limits of quantification (LLQ, ULQ).
Additionally, the power of definition (PD) can be calculated for every interval of interest (3, 5) . The PD allows one to determine which differences in subsequent values represent significant (with. p > 0.95) changes at each defmed interval of the analytical ränge.
In this paper we applied a standardized mathematical procedure for the assessment of the performance of the cocaine metabolite (benzoylecgoniiie) assay, which is based on a fluorescence Polarisation immunoassay.
The term 'analytical sensitivity* of the method is critically discussed both in relation to the consequences of the definition of the cut-off at different levels and with respect to the diagnostic sensitivity and specificity of the screening procedure for the abuse of cocaine. An alternative procedure for the definition of the threshold value is proposed.
Materials and Methods
Hundred urine samples of people suspected of cocaine abuse when entering a drug rehabilitation centre ('patients' group) were analyzed in triplicates with the Abbott TDx (fluorescence Polarisation immunoassay, FPIA; Abbott Laboratories, North Chicago). In addition 50 urine samples from patients from the intensive care unit were included in the study. These patients were being treated with several different therapeutic drugs, but an abuse of cocaine could be excluded ('contfoT group).
The FPIA-method and the Instrument technology has beeil de-; scribed in detail elsewhere (6) . The TDx uses a six-point calibration curve and prints out quantitative results.
In ofder to calculate the diagnostic sensitivity and specificity of the procedure, the test results of these two patient groups were attributed to 13 different classes frorn l .6 to > 400 g/l and plotted using the Computer program of Abendroth et al. (7) . Diagnostic sensitivity, diagnostic specificity and negative and positive predictive values of the screening procedure for the cocaine metabolite were calculated for four different cut^off values.
The variance function and the corresponding confidence interval were derived from triplicate measurements of patient samples using the computer-prograrn by Sadler & Smith (8) . The analytical variance can be assessed with a minimum of duplicate measurements. By increasing the number of repetitions, the meaning of each individual coefficient of Variation (CV) can be increased. Triplicate measurements were chosen äs a compromise between the need to obtain a meaningful CV for every sample and the need to limit the reagent costs for such a study.
The calculation of the precision profile, the lower limit of quantification (LLQ), the limit of detection (LD) and the power of definition (PD) has been described previously (3) and a normal distribution with the respective Standard deviation can be constructed. Using an iterative mathematical procedure (Newton-Rawson-procQdure (9)) the adjacent normal distribution with a defuied overlap of 5% is constructed. The peak value of this second normal distribution represents the LD. The intersection of the two normal distributions represent the critical limit (LC) ( fig. 3 ).
In order to determine the PD for each interval of interest, a series of normal distributions can be constructed, each overlapping the previous by e. g. 5%. The PD is a measure for the 'analytical sensitivity' of the method for a distinct interval. The programs for the calculation of LC, LD, LLQ and PD were developed using the Computer program 'Microsoft® Excel, version 4.0*. . From this variance function the precision profile could be derived, s shown in figure 2.
Results
The determination of the lower limit of quantiflcation (LLQ) was performed according to the procedure shown in the enlargement in figure 2. The LLQ was determined to be 39 μ §/1 (10% CV) or 92 μ^ (5% CV). The upper limit of quantiflcation for this assay is given by the concentration of the highest calibrator (1000 μg/l) and not by the performance of the assay, since the CV at an analyte concentration of 1000 μg/l is 1.8%.
The coefficients of Variation at analyte concentrations that will be discussed s potential cut-off limits were calculated t be: 25.8% (12 μg/l); 8.5% (40 jig/l); 3.1% (150 μg/l); 2.2% (300 fig. 1 . In the blow up, the determination of the lower limit of quantiflcation (LLQ) is shown. Fig. 3 Construction of the normal distribution of the blank and the adjacent normal distribution following the variance formula and overlapping the zero-distribution by 5%.
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The Standard deviation of the assay at a benzoylecgonine concentration of zero was calculated by the variance function (s(0) = 2.96) and used for the construction of a normal distribution at an analyte concentration of zero ( fig. 3 ). The intersection of the adjacent normal distribution, overlapping the 'blank normal distribution' by 5%, represents the critical limit (LC). At this point the probability for the presence of the analyte equals the probability for the absence of the analyte. It was found to be 5.8 μg/l. The limit of detection (LD), where the probability for the detection of the analyte is ^ 95%, is represented by the peak value of the second normal distribution. LD was found to be 11.9 μg/l. The CV at this concentration is 26.0%.
For every interval of the analytical r nge, consecutive normal distributions, each overlapping the preceeding by 5%, can be constructed (fig. 4) . Tlie number of normal distributions, which equals the power of de nition (PD), represents the number of benzoylecgonine values which can be discriminated with a probability of ^ 95% in a certain interval. In the interval 100-500 μg/l, the PD is 16, in the interval 400-500 μ §/1, the PD was found to\be only = 3.
The power of definition at the cut-off value (according to NIDA = 300 μ §/1 (10)) is shown in the enlarged section of figure 4 . The values which can be discriminated from 300 μg/l with p > 95% are < 274.7 μg/l or > 326.7 μ §/1.
B. Diagnostic performance of the cocaine metabolite screening
The benzyolecgonine values found for the 50 samples from patients of the intensive care unit who were under treatment for a wide spectrum of different therapeutic drugs (population of the 'non-diseased') ranged from 0.0 to 9.8 μg/l, whereas in the cocain addicted population ('diseased') values from 0 μg/l to 586 mg/1 were observed. The distribution of the values in the two populations is plotted in figure 5 . Sensitivity, specificity and positive and negative predictive values were calculated for four different cut-off values (tab. 1).
The diagnostic Sensitivity of the screening procedure is highest (0.926) with a cut-off close to the limit of detection of the method and decreases dramatically to less than 0.5 (0.488) with the cut-off recommended by NIDA (300
With none of the cut-offs used for further calculations, a false positive classification of a patient resulted and the specificity of the screening was therefore uniformly = 1.0.
A consequence of the 100% specificity of the screening is that the predictive value of the positive result is uniformly = 1.0. The predictive value of the negative result depends on the diagnostic Sensitivity of the procedure and on the prevalence of the drug abuse. Predictive values of the negative result for an assumed prevalence of 0.5 are given in table 1.
Discussion
Immunological tests for the quantification of drugs of abuse were first iiitroduced s radioimmunoassays in 1970 for the determination of morphine in urine (11) . A large scale screening was made possible in m iiy laboratories only when non-radioactive immunoassays for drug testing became commercially available and the degree of a tomation could be significantly improved. (12), whereas recently issued immunoassays are much more sensitive. For the FPIA method e. g., a LD of 0.03 mg/1 has been reported (13) . By modifying the calibration procedure of the Abbott TDx method for the cocaine metabolite a decrease of the LD to 0.027 mg/1 could be achieved (14) .
The antibody used in the cocaine metabolite assay from Abbott is highly specific for benzoylecgonine, the primary urinary metabolite of cocaine. Cross reactivity has to be expected for cocaine (0.4-0.8%), ecgonine (0.3%) and ecgonine methylester (<0.1% (13)). Only a few substances unrelated to cocaine may cause significant positive interference with immunoassays for benzoylecgonine, e. g. phenothiazines (chlorpromazine and thioridazine) and tricyclic antidepressants (amitriptyline). But these drugs must be present at unlikely concentrations on the order of 100 mg/1 (15) (16) (17) .
If this model were to be used for group-specific tests (e. g. benzodiazepines) one or more compounds (metabolites) must be selected to assess the performance ofthe assay. The anälytical result could be related to a major component for which the antibody used in the test is specific.
We assessed the anälytical perfonnance ofthe FPlA assay using a standardized mathematical procedure for the determination of the variance function. This procedure is based on human sample material. No Standards with artificial rnatrices had to be used. The main problem in estimating the limit of detection lies in obtaining an adequate blank (18) . This problem can be elegantly solved by extrapolating the variance function to zero. From the variance function the critical limit (LC), the limit of detection (LD) and the lower (and upper) limit of quantification (LLQ) can be derived according to a procedure which has been previously described in detail (3, 5, 19) . This procedure is very compatible with IFCC recommendations (20) , which defme the limit of detection äs a quantity which should be set where "the value can be distinguished from the blank with a stated probability"<.
The performance of an anälytical method whose results may have such severe consequences (not getting a Job, loss of Job, etc.) should, in our opinion, be assessed using a highly approved and standardized mathematical procedure.
Most of the authors and reagent manufacturers who report on the limit of detection either do not describe the method used to obtain the LD and/or use artificial Standard material for its determination.
Limits of detection calculated from repetitive measurements of a 'zero-calibrator' by adding 2 Standard deviations (21) or 3 Standard deviations (22) to the mean (obtained by a repetitive measurement of a 'blank' sample), in our terminology rather represent the critical limit, where the probability for a false positive estimate is e. g. 5% (2 s) or Ä 1% (3 s). Repetitive measurements of the zero calibrator deliver at best an imprecision of the 'System noise', which might follow a normal distribution. Limits based on a certain Standard deviation of these measurements therefore represent no more than an exclusion criterion.
In our approach, the limit of detection was set where the probability for detection of the analyte is ^ 95% (fig.  3 ). It is, however, important to mention that results in the ränge of the LD are still burdened with a high imprecision (26.0% at LD). It is therefore necessary to define a CV which is acceptable from a diagnostic point of view and hence to determine the lower limit of quantification, which is significantly different from the LD ( fig. 2 ).
Most results from drug screening are not given äs quantitative values, but rather in a nominal form äs 'positive' or 'negative'. The decision limit (cut-ofif) used by most laboratories to obtain this binary result is based on NIDA specifications origirially issued in 1988 (10) . These cut-off recommendations have not been altered, despite the fact that detectability (often falsely called 'sensitivity') and specificity ofthe test Systems currently used have been substantially improved.
As stated by Fuentes-Arderiit, the term 'sensitivity' is "... most confusing in clinical chemistry ..." (18) . The majority of authors use it when referring to the limit of detection, in contradiction to international metrological organizations. According to ISO (23) , anälytical sensitivity is "... the change in response of a measuring instrument divided by the corresponding change in Stimulus ...". The same is claimed in.other words by IUPAC (24): "... sensitivity is the slope ofthe anälytical calibra-tion curve ...". Sensitivity defmed according to these recommendations is of great importance for test design, but useless for test applications under routine conditions. Here the power of definition is of crucial benefit, because it includes both the slope of the calibration curve (the true sensitivity) and the corresponding variability, e. g. äs confidence intervals.
Recommendations issued by the United States Department of Defense in 1993 (directive 1010.1) (25) take the analytical improvement at least partly into account and suggest that the cut-off for the cocaine metabolite assay be lowered to 150 g/l. The level of the chosen cut-off has a substantial impact on the diagnostic sensitivity of the screening procedure, äs shown in figure 5 and table 1. Finkle et al. stated that the threshold concentrations are selected on the basis of 'administrative' and 'pro·-grammatic' needs (26) . In our view, the purpose of screening for an abuse of drugs should be to detect äs many recent drug abuses äs possible. The results shown in table l demonstrate that the diagnostic sensitivity increases substantially if the cut-off is moved to lower values. By lowering the cut-off to 40 g/l (which is close to LLQ, if a CV of 10% is accepted) a diagnostic sensitivity of 0.843 could be achieved and the predictive value of the negative result could be improved to 0.864 (in a collective with a prevalence for an abuse of cocaine of 0.50) while the diagnostic specificity and the predictive value of the positive result would remain unchanged (= 1.0).
As suggested by others (19, 25) , we are convinced that decision levels for the screening for an abuse of cocaine should be lowered. Hallbach & Guder proposed '... to use the detection limit äs decision limit ...' (27) . Taking the usually high imprecision of LD into account, we would recommend the use of LLQ äs the decision limit (cut-off).
Modern analytical Systems for drug screenings are based on the same principles äs assays for the determination of hormones, tumour markers and therapeutic drugs. All of these assays are established äs true quantitative methods for diagnostic pufposes. Nevertheless, the tnanufacturers label their drug-screening assays äs 'qualitative' or even äs 'semiquantitative' tests, äs is usually done for urine test Strips. But äs stated by Dybkaer (28) "... these terms are ambiguous and give insufficient Information ..." and should therefore be avoided.
Very much care is taken to avoid false positive test results. The users of the test kits are urged to confinn each positive result by a so called 'confifmation test', despite the fact that imprecision äs well äs detectability of the recommended analytical Systems (GC, HPLC) is in many cases worse compared to modern immunological Systems, especially in the case of the cocaine metabolite assäy where the immunological test is highly specific (29) . The medical or forensic screening of (suspected) drug äddicts involves a special difficulty in so far äs if an abuse of drugs is stated, portentous psychological, social, economical and judiciäl consequences miglit result. False results (especially false positives) may even involve the liability for compensation. This might explain why mänufacturers of Systems for the screening for drugs of abuse advise caution when interpreting test results and do not object to the use of outdated cutoff values.
But it seems to be important to emphasise the fact that official documents urge drug testing laboratories not only to minimize their number of false positive test results by using confirmation procedures, but also state that the number of false negative results has to be kept < 10% (10) .
The data presented hefe demonstrate that -using the NID A cut-off value -almost half of the urine samples with benzoylecgonine concentrations well above LD are classified äs 'negative'. This kind of false negative results can only be minimized if the decision limit is considerably lowered and adapted to the actual analytical state of the art.
